Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Affymax, Inc.
Phase II trial of Hematide for anemia begins
August 10th, 2005
Affymax, Inc., announced that it has begun enrollment of patients in a second phase II trial of its lead investigational product Hematide, a synthetic, peptide-based erythropoiesis stimulating agent (ESA), which is being developed to stimulate production of red blood cells for the treatment of anemia in patients with chronic kidney disease (CKD) and cancer. This open-label, multicenter, dose-finding study is being conducted at several clinical sites in the U.S. under an U.S. Food & Drug Administration (FDA)-approved Investigational New Drug (IND) application. The study will evaluate the safety, pharmacodynamics and pharmacokinetics of repeat intravenous injections of...
Source: Biotech Week (2005-08-10)
|
